TXMD — TherapeuticsMD Share Price
0.000.00%
Last trade - 00:00- $18.94m
- $13.71m
- $1.30m
- 20
- 33
- 45
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 4.69 | ||
| PEG Ratio (f) | 0.06 | ||
| EPS Growth (f) | 273.15% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.3% | ||
| Return on Equity | -16.42% | ||
| Operating Margin | -699.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 49.65 | 64.87 | 2.57 | 69.96 | 1.3 | 9 | 9.1 | -39.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Directors
- Thomas Thompson NEC (79)
- Hugh O Dowd CEO (56)
- Robert Finizio VCH (50)
- James D'Arecca CFO (50)
- Michael Donegan VFN (53)
- Marlan Walker GCN (46)
- Mark Glickman OTH (51)
- John Milligan SEC (58)
- Paul Bisaro IND (60)
- Cooper Collins IND (42)
- Karen Ling IND (57)
- Jules Musing IND (73)
- Gail Naughton IND (65)
- Angus Russell IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 20th, 2010
- Public Since
- January 31st, 2001
- No. of Shareholders
- 80
- No. of Employees
- 1
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 11,532,432
- Address
- 951 Yamato Road, Suite 220, BOCA RATON, 33431
- Web
- https://www.therapeuticsmd.com/
- Phone
- +1 5619611900
- Auditors
- Berkowitz Pollack Brant
Upcoming Events for TXMD
Q4 2024 TherapeuticsMD Inc Earnings Release
Similar to TXMD
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the TherapeuticsMD share price?
As of Today at 23:40 UTC, shares in TherapeuticsMD are trading at $1.64. This share price information is delayed by 15 minutes.
How has the TherapeuticsMD share price performed this year?
Shares in TherapeuticsMD last closed at $1.64 and the price had moved by -40.27% over the past 365 days. In terms of relative price strength the TherapeuticsMD share price has underperformed the S&P500 Index by -55.25% over the past year.
What are the analyst and broker recommendations for TherapeuticsMD?
The overall consensus recommendation for TherapeuticsMD is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the TherapeuticsMD dividend yield?
TherapeuticsMD does not currently pay a dividend.
Does TherapeuticsMD pay a dividend?
TherapeuticsMD does not currently pay a dividend.
When does TherapeuticsMD next pay dividends?
TherapeuticsMD does not currently pay a dividend.
How do I buy TherapeuticsMD shares?
To buy shares in TherapeuticsMD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TherapeuticsMD?
As of the previous close price of $1.64, shares in TherapeuticsMD had a market capitalisation of $18.94m.
Where are TherapeuticsMD shares listed?
Here are the trading details for TherapeuticsMD:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TXMD
What kind of share is TherapeuticsMD?
Based on an overall assessment of its quality, value and momentum TherapeuticsMD is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TherapeuticsMD share price forecast for 2024?
The analyst consensus target price for shares in TherapeuticsMD is $5.00. That is 204.41% above the last closing price of $1.64.
Analysts covering TherapeuticsMD currently have a consensus Earnings Per Share (EPS) forecast of $0.35 for the next financial year.
Find out moreWhat is the trend in the TherapeuticsMD share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TherapeuticsMD. Over the past six months, its share price has underperformed the S&P500 Index by -32.62%.
As of the last closing price of $1.64, shares in TherapeuticsMD were trading -18.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TherapeuticsMD PE Ratio?
The TherapeuticsMD PE ratio based on its reported earnings over the past 12 months is 4.69. The shares last closed at $1.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TherapeuticsMD?
TherapeuticsMD's management team is headed by:
- Thomas Thompson - NEC
- Hugh O Dowd - CEO
- Robert Finizio - VCH
- James D'Arecca - CFO
- Michael Donegan - VFN
- Marlan Walker - GCN
- Mark Glickman - OTH
- John Milligan - SEC
- Paul Bisaro - IND
- Cooper Collins - IND
- Karen Ling - IND
- Jules Musing - IND
- Gail Naughton - IND
- Angus Russell - IND